BioTime (BTX) Reports Q4 Loss of $0.58/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St futures tick higher after tech rout; Mideast, tariffs in focus
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, but set for weekly rise on Middle East escalation
- Meta’s new seller app hits eBay where it hurts most
- American Express down 2% in premarket trade after Q2 revenue miss offsets EPS beat
BioTime Reports Fourth Quarter and Fiscal 2017 Results
March 15, 2018 4:06 PM EDTRenevia® CE Mark application submitted for European approval OpRegen® receives DSMB approval to proceed to cohort 4 OpRegen® cohort 4 will include better vision patients and an array of additional functional assessments
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.
2017 was a successful year for BioTime, capped by our recent European CE Mark submission of Renevia® and... More
